Correlation Between Salesforce and Cytek Biosciences

Can any of the company-specific risk be diversified away by investing in both Salesforce and Cytek Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Salesforce and Cytek Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Salesforce and Cytek Biosciences, you can compare the effects of market volatilities on Salesforce and Cytek Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Salesforce with a short position of Cytek Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Salesforce and Cytek Biosciences.

Diversification Opportunities for Salesforce and Cytek Biosciences

-0.47

Correlation Coefficient

Salesforce  Cytek Biosciences

Very good diversification

The 3 months correlation between Salesforce and Cytek is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Salesforce and Cytek Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytek Biosciences and Salesforce is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Salesforce are associated (or correlated) with Cytek Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytek Biosciences has no effect on the direction of Salesforce i.e., Salesforce and Cytek Biosciences go up and down completely randomly.

Pair Corralation between Salesforce and Cytek Biosciences

Considering the 90-day investment horizon Salesforce is expected to generate 0.34 times more return on investment than Cytek Biosciences. However, Salesforce is 2.96 times less risky than Cytek Biosciences. It trades about 0.11 of its potential returns per unit of risk. Cytek Biosciences is currently generating about -0.03 per unit of risk. If you would invest  23,589  in Salesforce on April 21, 2025 and sell it today you would earn a total of  2,649  from holding Salesforce or generate 11.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Salesforce  vs.  Cytek Biosciences

Salesforce

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Salesforce are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Salesforce may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Cytek Biosciences

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cytek Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's forward-looking signals remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Salesforce and Cytek Biosciences

The main advantage of trading using opposite Salesforce and Cytek Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Salesforce position performs unexpectedly, Cytek Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytek Biosciences will offset losses from the drop in Cytek Biosciences' long position.

The idea behind Salesforce and Cytek Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.